| 000 | 01932 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516160814.0 | ||
| 264 | 0 | _c20131028 | |
| 008 | 201310s 0 0 eng d | ||
| 022 | _a1471-2377 | ||
| 024 | 7 |
_a10.1186/1471-2377-13-82 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMuñoz, Delicias | |
| 245 | 0 | 0 |
_aAdverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers. _h[electronic resource] |
| 260 |
_bBMC neurology _cJul 2013 |
||
| 300 |
_a82 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a2',5'-Oligoadenylate Synthetase _xmetabolism |
| 650 | 0 | 4 | _aBody Mass Index |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadverse effects |
| 650 | 0 | 4 |
_aInterferon-beta _xadverse effects |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Chronic Progressive _xdrug therapy |
| 650 | 0 | 4 |
_aNeopterin _xmetabolism |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_abeta 2-Microglobulin _xmetabolism |
| 700 | 1 | _aEscartín, Antonio | |
| 700 | 1 | _aDapena, Dolores | |
| 700 | 1 | _aCoret, Francisco | |
| 700 | 1 | _aFernández-Uría, Dionisio | |
| 700 | 1 | _aPérez, Domingo | |
| 700 | 1 | _aCasanova, Bonaventura | |
| 700 | 1 | _aGuijarro-Castro, Cristina | |
| 700 | 1 | _aMunteis, Elvira | |
| 700 | 1 | _adel-Campo Amigo, María | |
| 700 | 1 | _aPego, Robustiano | |
| 700 | 1 | _aCalles, Carmen | |
| 700 | 1 | _aGarcía-Rey, César | |
| 700 | 1 | _aMonsalve, Nuria | |
| 700 | 1 | _aSánchez-Matienzo, David | |
| 773 | 0 |
_tBMC neurology _gvol. 13 _gp. 82 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2377-13-82 _zAvailable from publisher's website |
| 999 |
_c22909317 _d22909317 |
||